Final data collection for primary outcome measures is anticipated in September for ZUMA-2, a Phase II multicenter study of the chimeric antigen receptor (CAR) T-cell product KTE-C19 in patients with relapsed/refractory mantle cell lymphoma.
ZUMA-2 (NCT02601313), with a planned enrollment of 70 patients, is expected to release the overall response rate at 12 months. Secondary outcome measures include duration of response, best objective response, and progression-free survival.
National Institutes of Health
Subjects can have up to five prior regimens, which must include anthracycline or bendamustine-containing chemotherapy, anti-CD20 monoclonal antibody therapy, and ibrutinib. Study subjects cannot have received allogeneic stem cell transplantation, prior CD19 targeted therapy, or prior CAR or other genetically modified T cell therapy.
Trial participants must be adults with an Eastern cooperative oncology group (ECOG) performance status of 0 or 1, an absolute neutrophil count of at least 1000/µL, and a platelet count of at least 50,000/µL. All need to have adequate renal function, defined as a serum creatinine of 1.5 mg/dL or less; adequate hepatic function, defined as a serum ALT/AST of 2.5 the upper limit of normal or less; and a total bilirubin of 1.5 mg/dL or less (except in subjects with Gilbert’s syndrome), and adequate cardiac function, defined as a cardiac ejection fraction of 50% or more with no evidence of pericardial effusion.
Exclusion criteria include a history of another cancer other than nonmelanomatous skin cancer or carcinoma in situ (for example, cervix, bladder, breast) unless disease free for at least 3 years, known infection with HIV or hepatitis B or C virus, metastases in cerebrospinal fluid or brain, and a history of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
The study is sponsored by Kite Pharma, the makers of KTE-C19.